RECRUITING

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

Official Title

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Quick Facts

Study Start:2020-11-03

Study Completion:2026-07-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04513028

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED). * Must be treatment naïve or have had treatment no less than 6 months prior to enrollment * 18 years or older * Must be able to take pills * ECOG performance status of 0-3 * Ability to understand and willingness to sign a written informed consent * Members of all racial and ethnic groups are eligible for this study	* History of hypersensitivity reactions attributed to beta-glucan * Patients receiving continuous or other ongoing immunosuppressive therapy * Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately * Patients with mucosal melanoma * Patients with concurrent malignancy or recent history thereof

Inclusion Criteria

Exclusion Criteria

* Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED).
* Must be treatment naïve or have had treatment no less than 6 months prior to enrollment
* 18 years or older
* Must be able to take pills
* ECOG performance status of 0-3
* Ability to understand and willingness to sign a written informed consent
* Members of all racial and ethnic groups are eligible for this study

* History of hypersensitivity reactions attributed to beta-glucan
* Patients receiving continuous or other ongoing immunosuppressive therapy
* Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately
* Patients with mucosal melanoma
* Patients with concurrent malignancy or recent history thereof

Contacts and Locations

Study Contact

Matthew Woeste, MD

CONTACT

502-852-0325

matthew.woeste@louisville.edu

Principal Investigator

Kelly M McMasters, MD

PRINCIPAL_INVESTIGATOR

University of Louisville

Study Locations (Sites)

University of Louisville

Louisville, Kentucky, 40202

United States

Collaborators and Investigators

Sponsor: Kelly McMasters

Kelly M McMasters, MD, PRINCIPAL_INVESTIGATOR, University of Louisville

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-11-03

Study Completion Date2026-07-31

Study Record Updates

Study Start Date2020-11-03

Study Completion Date2026-07-31

Terms related to this study

Additional Relevant MeSH Terms

Melanoma Stage III
Melanoma Stage IV